Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $24.1 million.

  • Ligand Pharmaceuticals' Accumulated Expenses rose 5438.46% to $24.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.1 million, marking a year-over-year increase of 5438.46%. This contributed to the annual value of $27.9 million for FY2024, which is 12383.89% up from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Accumulated Expenses stood at $24.1 million, which was up 5438.46% from $17.5 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' Accumulated Expenses' 5-year high stood at $27.9 million during Q4 2024, with a 5-year trough of $7.3 million in Q2 2023.
  • Its 5-year average for Accumulated Expenses is $15.6 million, with a median of $15.0 million in 2023.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first tumbled by 4989.35% in 2023, then soared by 12383.89% in 2024.
  • Ligand Pharmaceuticals' Accumulated Expenses (Quarter) stood at $17.6 million in 2021, then decreased by 10.8% to $15.7 million in 2022, then dropped by 20.5% to $12.5 million in 2023, then surged by 123.84% to $27.9 million in 2024, then decreased by 13.7% to $24.1 million in 2025.
  • Its last three reported values are $24.1 million in Q3 2025, $17.5 million for Q2 2025, and $23.5 million during Q1 2025.